[go: up one dir, main page]

WO2007121389A3 - Inhibiteurs des transporteurs de la nk-1 et de la sérotonine - Google Patents

Inhibiteurs des transporteurs de la nk-1 et de la sérotonine Download PDF

Info

Publication number
WO2007121389A3
WO2007121389A3 PCT/US2007/066682 US2007066682W WO2007121389A3 WO 2007121389 A3 WO2007121389 A3 WO 2007121389A3 US 2007066682 W US2007066682 W US 2007066682W WO 2007121389 A3 WO2007121389 A3 WO 2007121389A3
Authority
WO
WIPO (PCT)
Prior art keywords
piperidine derivatives
serotonin transporter
transporter inhibitors
disubstituted piperidine
serotonin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2007/066682
Other languages
English (en)
Other versions
WO2007121389A2 (fr
Inventor
Derek J Denhart
Andrew P Degnan
George O Tora
Ying Han
Rajamani Ramkumar
Jonathan L Ditta
Kevin W Gillman
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bristol Myers Squibb Co
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of WO2007121389A2 publication Critical patent/WO2007121389A2/fr
Publication of WO2007121389A3 publication Critical patent/WO2007121389A3/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D211/20—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms
    • C07D211/22—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms by oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

L'invention concerne des composés de formule I, y compris leurs sels pharmaceutiquement acceptables, des compositions pharmaceutiques les contenant, ainsi que leur utilisation dans le traitement de troubles associés à un excès ou un déséquilibre des tachykinines ou de la sérotonine ou des deux. [ I ]
PCT/US2007/066682 2006-04-17 2007-04-16 Inhibiteurs des transporteurs de la nk-1 et de la sérotonine Ceased WO2007121389A2 (fr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US79260406P 2006-04-17 2006-04-17
US60/792,604 2006-04-17
US11/734,809 2007-04-13
US11/734,809 US20070249607A1 (en) 2006-04-17 2007-04-13 Nk-1 and serotonin transporter inhibitors

Publications (2)

Publication Number Publication Date
WO2007121389A2 WO2007121389A2 (fr) 2007-10-25
WO2007121389A3 true WO2007121389A3 (fr) 2008-02-21

Family

ID=38510473

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2007/066682 Ceased WO2007121389A2 (fr) 2006-04-17 2007-04-16 Inhibiteurs des transporteurs de la nk-1 et de la sérotonine

Country Status (5)

Country Link
US (2) US20070249607A1 (fr)
AR (1) AR060496A1 (fr)
PE (1) PE20071225A1 (fr)
TW (1) TW200811135A (fr)
WO (1) WO2007121389A2 (fr)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8071778B2 (en) * 2006-07-27 2011-12-06 Bristol-Myers Squibb Company Substituted heterocyclic ethers and their use in CNS disorders
CN101495470A (zh) * 2006-07-27 2009-07-29 百时美施贵宝公司 4-芳基烷氧基甲基-4-苯基哌啶及其作为神经激肽受体拮抗剂治疗cns疾病的用途
ES2601856T3 (es) 2007-06-08 2017-02-16 Mannkind Corporation Inhibidores de la IRE-1A
US20090018163A1 (en) * 2007-07-11 2009-01-15 Bristol-Myers Squibb Company Substituted Heterocyclic Ethers and Their Use in CNS Disorders
US8026257B2 (en) * 2007-07-11 2011-09-27 Bristol-Myers Squibb Company Substituted heterocyclic ethers and their use in CNS disorders
US7632861B2 (en) * 2007-11-13 2009-12-15 Bristol-Myers Squibb Company Substituted heterocyclic ethers and their use in CNS disorders
WO2009096941A1 (fr) * 2008-01-28 2009-08-06 Bristol-Myers Squibb Company Éthers hétérocycliques substitués et leur utilisation dans des troubles du système nerveux central
WO2010056938A1 (fr) * 2008-11-14 2010-05-20 Theravance, Inc. Procédé de préparation de composés à base de 4-[2-(2-fluorophénoxy­méthyl)phényl]pipéridine
CN110662541B (zh) * 2017-03-12 2023-02-10 王晓冬 多环胺作为阿片受体调节剂

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5620989A (en) * 1992-10-28 1997-04-15 Merck Sharp & Dohme Limited 4-Arylmethyloxymethyl piperidines as tachykinin antagonsits
US20040072867A1 (en) * 2002-07-03 2004-04-15 Schering Corporation NK1 antagonists

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1337418C (fr) 1988-03-28 1995-10-24 Engelbert Ciganek 4-aryl-4piperidine(ou pyrrolidine ou hexahydroazepine) cardinols et leurs analogues heterocycliques
WO1995019344A1 (fr) * 1994-01-13 1995-07-20 Merck Sharp & Dohme Limited Antagonistes de tachykinine azacycliques a double substitution gem
PE20040682A1 (es) 2002-03-13 2004-10-07 Schering Corp Derivados de ciclobutano como antagonistas de nk1
JP2006502157A (ja) 2002-09-09 2006-01-19 アストラゼネカ・アクチエボラーグ ナフチルエーテル化合物及びそれらの使用
US7098203B2 (en) * 2004-07-20 2006-08-29 Bristol-Myers Squibb Company Homopiperidine derivatives as NK-1 antagonists
US7138423B2 (en) * 2004-07-20 2006-11-21 Bristol-Myers Squibb Company Arylpyrrolidine derivatives as NK-1 /SSRI antagonists
US7276631B2 (en) * 2004-07-20 2007-10-02 Bristol-Myers Squibb Company Cyclopentylamine and cyclohexylamine derivatives as NK-1/SSRI antagonists
US7494986B2 (en) * 2004-07-20 2009-02-24 Bristol-Myers Squibb Company Cycloalkylamine derivatives as NK-1/SSRI antagonists

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5620989A (en) * 1992-10-28 1997-04-15 Merck Sharp & Dohme Limited 4-Arylmethyloxymethyl piperidines as tachykinin antagonsits
US20040072867A1 (en) * 2002-07-03 2004-04-15 Schering Corporation NK1 antagonists

Also Published As

Publication number Publication date
US8383821B2 (en) 2013-02-26
WO2007121389A2 (fr) 2007-10-25
TW200811135A (en) 2008-03-01
AR060496A1 (es) 2008-06-18
PE20071225A1 (es) 2008-01-14
US20070249607A1 (en) 2007-10-25
US20100087434A1 (en) 2010-04-08

Similar Documents

Publication Publication Date Title
WO2007121389A3 (fr) Inhibiteurs des transporteurs de la nk-1 et de la sérotonine
WO2009144555A8 (fr) Inhibiteurs de la pyrazolospirocétone acétyl-coa carboxylase
WO2008022286A3 (fr) petits inhibiteurs moléculaires de la kynurénine-3-monooxygénase
MX2009005604A (es) Inhibidores espiro cetona de acetil-coa carboxilasa.
WO2009155121A3 (fr) Inhibiteurs de la pi3 kinase
UA92670C2 (ru) Пиразолиновые соединения и их фармацевтическое применение, композиция на их основе
WO2009046841A8 (fr) Dérivés de pipéridine et de pipérazine
WO2007092364A3 (fr) Agonistes du recepteur de la niacine, compositions contenant de tels composes et procedes de traitement
WO2010044981A3 (fr) Inhibiteurs benzoquinoline du transporteur de monoamines vésiculaire 2
IL189191A0 (en) Thiazolyl piperidine derivatives useful as h3 receptor modulators
WO2007120575A3 (fr) Agonistes du récepteur de la niacine, compositions contenant de tels composés et méthodes de traitement
WO2009023539A3 (fr) Dérivés amides utilisés comme antagonistes des trpv1
IL196543A (en) Pyridazinone derivatives, pharmaceutical preparations containing them for use in the treatment of disorders
WO2009065922A3 (fr) Nouveaux composés
WO2007126900A3 (fr) Agents antifongiques
NO20080033L (no) Kinolinderivater som NK3-antagonister
WO2008011113A3 (fr) Dérivés de thiadiazolidinone
WO2007131907A3 (fr) Dérivés de 1h-indol-5-yl-pipérazin-1-yl-méthanone
WO2008145524A3 (fr) Dérivés de pipéridine 4,4-disubstituée
WO2008087654A3 (fr) PIPÉRIDINES EN TANT QU'INHIBITEURS DE 11β-HYDROXYSTÉROÏDE DÉSHYDROGÉNASE DE TYPE 1
ATE466842T1 (de) 3-substituierte pyridinderivate als h3- antagonisten
WO2004067703A3 (fr) Antagonistes 5ht7 et agonistes inverses
ATE412636T1 (de) Piperazinylpyridinderivate als mittel gegen adipositas
ATE449776T1 (de) Pyrroloä2,3-cüpyridinderivate
WO2010019203A8 (fr) Agents antifongiques

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 07760691

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 07760691

Country of ref document: EP

Kind code of ref document: A2